Literature DB >> 9464195

Two-year outcome of psychotic depression in late life.

A J Flint1, S L Rifat.   

Abstract

OBJECTIVE: The purpose of this study was to determine whether elderly patients with psychotic depression differed in long-term outcome from patients with nonpsychotic depression.
METHOD: The study group consisted of 19 patients with psychotic major depression who had responded to ECT (N = 15), nortriptyline and perphenazine (N = 2), or nortriptyline, perphenazine, and adjunctive lithium (N = 2) and 68 nonpsychotic depressed patients who had responded to either nortriptyline alone (N = 61) or nortriptyline and lithium (N = 7). All patients were maintained on regimens of full-dose nortriptyline. When prescribed for the index episode, adjunctive lithium was also maintained, but perphenazine was withdrawn 16 weeks after response. Patients were followed on a monthly basis for 2 years or until relapse or recurrence, whichever occurred first.
RESULTS: Patients with psychotic depression had a substantially higher frequency of relapse or recurrence of depression and a shorter time to these events than nonpsychotic depressed patients. At index assessment, patients with psychosis were more severely depressed and had had more prior episodes of depression, but these factors did not account for the difference in outcome between the two groups. Furthermore, before entering the study, none of the psychotic patients had received adequate treatment for the index episode of depression, and so their poor outcome could not be attributed to prior treatment resistance.
CONCLUSIONS: Even when they achieved remission and were maintained on a regimen of full-dose antidepressant medication, older patients with psychotic depression were at greater risk of relapse or recurrence than were their nonpsychotic counterparts. In particular, continuation/maintenance treatment with tricyclic monotherapy following response to ECT had limited efficacy in this group of patients. These findings raise important questions about the optimal treatment of psychotic depression in late life.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9464195     DOI: 10.1176/ajp.155.2.178

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  12 in total

Review 1.  Psychotic major depression: a benefit-risk assessment of treatment options.

Authors:  Audrey R Tyrka; Lawrence H Price; Marcelo F Mello; Andrea F Mello; Linda L Carpenter
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Relapse following successful electroconvulsive therapy for major depression: a meta-analysis.

Authors:  Ana Jelovac; Erik Kolshus; Declan M McLoughlin
Journal:  Neuropsychopharmacology       Date:  2013-06-18       Impact factor: 7.853

3.  Diagnostic consistency of major depression with psychosis across 10 years.

Authors:  Camilo J Ruggero; Roman Kotov; Gabrielle A Carlson; Marsha Tanenberg-Karant; David A González; Evelyn J Bromet
Journal:  J Clin Psychiatry       Date:  2011-08-09       Impact factor: 4.384

Review 4.  Evaluation of newer treatment interventions for psychotic depression.

Authors:  B L O'Neal; C L Smith; M Trivedi
Journal:  Curr Psychiatry Rep       Date:  2000-08       Impact factor: 5.285

5.  Gender differences in patients presenting with a single depressive episode according to ICD-10.

Authors:  Lars Vedel Kessing
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-03       Impact factor: 4.328

Review 6.  Challenges in the treatment of major depressive disorder with psychotic features.

Authors:  Anthony J Rothschild
Journal:  Schizophr Bull       Date:  2013-04-18       Impact factor: 9.306

7.  A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD).

Authors:  Barnett S Meyers; Alastair J Flint; Anthony J Rothschild; Benoit H Mulsant; Ellen M Whyte; Catherine Peasley-Miklus; Eros Papademetriou; Andrew C Leon; Moonseong Heo
Journal:  Arch Gen Psychiatry       Date:  2009-08

8.  A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures.

Authors:  Kristina M Deligiannidis; Anthony J Rothschild; Bruce A Barton; Aimee R Kroll-Desrosiers; Barnett S Meyers; Alastair J Flint; Ellen M Whyte; Benoit H Mulsant
Journal:  J Clin Psychiatry       Date:  2013-10       Impact factor: 4.384

Review 9.  [Electroconvulsive therapy as maintenance therapy and for prevention of recurrence in psychiatric disorders and Parkinson disease].

Authors:  Matthäus Willeit; Nicole Praschak-Rieder; Siegfried Kasper
Journal:  Wien Klin Wochenschr       Date:  2003-05-15       Impact factor: 1.704

10.  Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD II.

Authors:  Alastair J Flint; Barnett S Meyers; Anthony J Rothschild; Ellen M Whyte; Benoit H Mulsant; Matthew V Rudorfer; Patricia Marino
Journal:  BMC Psychiatry       Date:  2013-01-25       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.